Biotech | March 12, 2024
USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
It is the first autotaxin inhibitor to be investigated in cancer patients
It is the first autotaxin inhibitor to be investigated in cancer patients
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
ANVISA issues CGMP to Concord Biotech’s Unit I
Subscribe To Our Newsletter & Stay Updated
